• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro.
【24h】

Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro.

机译：体外传代后人恶性神经胶质瘤细胞免疫表型的变化。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although immunotherapeutic strategies against glioblastomas have been promising both in vitro and in animal models, similar successes have not been realized in human clinical trials. One reason may be that immunotherapeutic strategies are based on prior studies that primarily have used human glioblastoma cell lines passaged in vitro, which may not accurately reflect the in vivo properties of glioblastoma cells. In this report, we used flow cytometry to quantify the expression of immunological cell surface molecules on human glioblastomas directly ex vivo (prior to any in vitro culturing) and after varying passages in vitro. Furthermore, we used ELISA to quantitate cytokine secretion after various passages in vitro. We demonstrate that in vitro culturing of established cell lines led to increases in the cell surface expression of MHC class I and ICAM-1 and secretion of IL-6 and TGF-beta(2). Furthermore, there were significant changes in the expression of MHC class I, MHC class II, B7-2, ICAM-1, and FasL when comparing ex vivo tumor cells to those after a single passage in vitro. After passaging once in vitro, there were also significant changes in the secretion of TGF-beta(2) and IL-10. This report indicates that in vitro culturing leads to significant changes in both cell surface molecules and secreted cytokines, which are known to affect the ability of immune cells to initiate an anti-tumor immune response. These changes in the immunological phenotype of glioblastomas after in vitro culturing may in part explain the limited success of immunotherapeutic strategies against glioblastomas in human clinical trials. (c)2001 Elsevier Science.
机译：尽管针对胶质母细胞瘤的免疫治疗策略在体外和动物模型中都有希望，但在人类临床试验中尚未获得类似的成功。一个原因可能是免疫治疗策略是基于先前的研究，该研究主要使用了体外传代的人胶质母细胞瘤细胞系，这可能无法准确反映胶质母细胞瘤细胞的体内特性。在本报告中，我们使用流式细胞仪直接定量（在任何体外培养之前）和体外变化传代后在人胶质母细胞瘤上免疫细胞表面分子的表达。此外，我们使用ELISA定量体外传代后的细胞因子分泌。我们证明建立的细胞系的体外培养导致MHC I类和ICAM-1的细胞表面表达增加以及IL-6和TGF-beta（2）的分泌。此外，当将离体肿瘤细胞与体外单次传代后的细胞进行比较时，MHC I类，II类MHC，B7-2，ICAM-1和FasL的表达发生了显着变化。经过一次体外传代后，TGF-beta（2）和IL-10的分泌也发生了显着变化。该报告表明，体外培养导致细胞表面分子和分泌的细胞因子发生显着变化，已知这些变化会影响免疫细胞启动抗肿瘤免疫反应的能力。体外培养后，胶质母细胞瘤免疫表型的这些变化可能部分解释了在人类临床试验中针对胶质母细胞瘤的免疫治疗策略的成功有限。 （c）2001 Elsevier科学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号